Aurigene Oncology is a clinical stage biotech company focused on the discovery and development of novel and effective therapeutics for the treatment of cancer. They leverage expertise in oncology to benefit cancer patients worldwide.

Aurigene Oncology

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Gregory Frost

Halozyme Therapeutics, Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Metric
Company Name	Aurigene Oncology	Halozyme Therapeutics, Inc.	Alnylam Pharmaceuticals, Inc.
Symbol		HALO	ALNY
MSH ID	COM:AURIGENE	COM:HALOZYME	COM:ALNYLAM
Market	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology
Country	IN	US	US
Stage
Employee Count		373	2.10K
Website	aurigene.com	halozyme.com	alnylam.com
LinkedIn		halozyme-therapeutics-inc-
Founders

Metric
Market Cap		6.74B	32.60B
Enterprise Value
Monthly Web Traffic	15.55K	7.62K	55.97K
Web Traffic Growth	11.26	-0.80	0.89
Valuation
Raised Capital			900M

Metric
Revenue	829.25M	1.83B
Revenue (LTM)
Revenue (NTM)
Gross Profit	636.89M	1.52B
EBITDA	422.43M	-228.12M
Operating Income	337.57M	-282.18M
Net Income	281.59M	-440.24M
EPS	2.13	-3.52
Diluted EPS	2.10	-3.52
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.79	0.87
Operating Profit Margin	0.46	0.04
EBITDA Margin	0.51	-0.12
Net Profit Margin	0.39	-0.03
Return on Equity	2.05	1.67
Return on Assets	0.17	-0.02
Return on Capital Employed	0.22	0.03

COM:AURIGENE

Aurigene Oncology

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	17.53	-42.10
P/B Ratio	17.86	-129.43
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	9.34	16.84
EV Multiple	14.08	326.32

Metric
Days Sales Outstanding	101.60	68.92
Days Payables Outstanding	38.70	97.72
Days Inventory Outstanding	331.59	128.53
Operating Cycle	414.45	187.09
Cash Conversion Cycle	388.24	104.98
Asset Turnover	0.48	0.58

Metric
Operating Cash Flow	388.57M	104.16M
Free Cash Flow	373.28M	41.95M
Cash Flow to Debt	0.29	0.15
Operating Cash Flow/Sales	0.50	0.16
Free Cash Flow Yield	0.08	-0.00

Metric
Cash & Equivalents	118.37M	812.69M
Accounts Receivable	-3.34M	-87.94M
Inventory	127.60M	89.15M
Goodwill	416.82M
Debt to Capitalization	0.95	1.20
Debt to Assets	0.79	0.34
Current Ratio	7.63	3.14
Quick Ratio	6.21	3.07

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.04	0.13
R&D to Revenue	0.10	0.58
SG&A to Revenue		0.35